EP2568971B1 - Canagliflozin containing tablets - Google Patents
Canagliflozin containing tablets Download PDFInfo
- Publication number
- EP2568971B1 EP2568971B1 EP11725825.1A EP11725825A EP2568971B1 EP 2568971 B1 EP2568971 B1 EP 2568971B1 EP 11725825 A EP11725825 A EP 11725825A EP 2568971 B1 EP2568971 B1 EP 2568971B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- tablet
- amount
- present
- weight
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZLVUUHANEBJVJT-WUWVGITFSA-N CC(OCC([C@H]([C@@H]([C@H]1OC(C)=O)OC(C)=O)OC(C)=O)OC1(c1ccc(C)c(Cc2ccc(-c(cc3)ccc3F)[s]2)c1)OC)=O Chemical compound CC(OCC([C@H]([C@@H]([C@H]1OC(C)=O)OC(C)=O)OC(C)=O)OC1(c1ccc(C)c(Cc2ccc(-c(cc3)ccc3F)[s]2)c1)OC)=O ZLVUUHANEBJVJT-WUWVGITFSA-N 0.000 description 1
- XYBGJUIUCFENGS-ODFVMSNBSA-N CC(OCC([C@H]([C@@H]([C@H]1OC(C)=O)OC(C)=O)OC(C)=O)OC1c1ccc(C)c(Cc2ccc(-c(cc3)ccc3F)[s]2)c1)=O Chemical compound CC(OCC([C@H]([C@@H]([C@H]1OC(C)=O)OC(C)=O)OC(C)=O)OC1c1ccc(C)c(Cc2ccc(-c(cc3)ccc3F)[s]2)c1)=O XYBGJUIUCFENGS-ODFVMSNBSA-N 0.000 description 1
- BMCTTYYZRZNFKY-AENJIMJJSA-N CC(O[C@H]([C@H]([C@H](c1ccc(C)c(Cc2ccc(-c(cc3)ccc3F)[s]2)c1)O/C1=C\OC(C)=O)OC(C)=O)[C@@H]1OC(C)=O)=O Chemical compound CC(O[C@H]([C@H]([C@H](c1ccc(C)c(Cc2ccc(-c(cc3)ccc3F)[s]2)c1)O/C1=C\OC(C)=O)OC(C)=O)[C@@H]1OC(C)=O)=O BMCTTYYZRZNFKY-AENJIMJJSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a tablet containing a 1-( ⁇ -D-glucopyranosyl)-3-(phenylthienylmethyl)benzene derivative or a pharmaceutically acceptable salt thereof that can be used in the treatment of diabetes mellitus, obesity, diabetic complications, and the related diseases.
- WO 2009/022010 A1 relates to a pharmaceutical composition comprising a SGLT2 inhibitor in combination with a dipeptidyl peptidase -IV (DPP-IV) inhibitor.
- DPP-IV dipeptidyl peptidase -IV
- WO 2005/012326 pamphlet discloses a class of compounds that are inhibitors of sodium-dependent glucose transporter (SGLT) and thus of therapeutic use for treatment of diabetes, obesity, diabetic complications, and the like.
- SGLT sodium-dependent glucose transporter
- WO 2005/012326 pamphlet describes 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene having the following formula:
- the present invention relates to a tablet as defined in the appended claims with high drug loading including a 1-( ⁇ -D-glucopyranosyl)-3-(phenylthienylmethyl)benzene derivative represented by formula (A): or a pharmaceutically acceptable salt thereof, as an active ingredient.
- the pharmaceutically acceptable salts of compound (A) include, for example, a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or a salt with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, etc.; or a salt with an acidic amino acid such as aspartic acid, glutamic acid, etc.
- an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.
- an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid
- pharmaceutically acceptable salts of the compound of formula (A) include an intramolecular salt, hydrate, solvate or polymorphism thereof.
- a pharmaceutically acceptable salt of compound (A) is hemihydrate.
- Compound (A) is also known as canagliflozin.
- the active pharmaceutical ingredient i.e., compound (A) or a pharmaceutically acceptable salt thereof, possesses activity as an inhibitor of the sodium dependent glucose transporters found in the intestine and kidney, and therefore the tablet of the present invention can be used in the treatment or prevention of patients, such as human patients, for diseases or disorders associated with SGLT activity.
- the tablet of the present invention can be used for the treatment, prevention or delaying the progression or onset of diabetes mellitus (such as type 1 and type 2 diabetes mellitus), diabetic complications (such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, atherosclerosis, or hypertension.
- diabetes mellitus such as type 1 and type 2 diabetes mellitus
- diabetic complications such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy
- delayed wound healing insulin resistance
- hyperglycemia hyperinsulinemia
- elevated blood levels of fatty acids elevated blood levels of glycerol
- hyperlipidemia obesity
- hypertriglyceridemia Syndrome X
- atherosclerosis or hypertension.
- the invention relates to a tablet as defined in the appended claims in the treatment or delaying the progression or onset of type II diabetes mellitus or obesity.
- the invention relates to the tablet as defined in the appended claims for use in treating or delaying the progression or onset of diseases associated with SGLT activity.
- the invention relates to the tablet as defined in the appended claims for use in treating or delaying the progression or onset of type II diabetes mellitus or obesity.
- the tablet of the present invention may contain additives generally used in pharmaceutical solid tablets.
- the additives include bulking agents (or fillers), disintegrants, binders, lubricants, coating agents, surfactants, flavors, colorants and sweetenings.
- Examples of the bulking agents or fillers suitable for use herein include lactose, sucrose, mannitol, xylitol, erythritol, sorbitol, maltitol, calcium citrate, calcium phosphate, and calcium aluminometasilicate.
- the bulking agents or fillers also include cellulose derivatives, such as microcrystalline cellulose or wood cellulose, lactose, sucrose, starch, pregelatinized starch, dextrose, mannitol, fructose, xylitol, sorbitol, corn starch, modified corn starch, inorganic salts such as calcium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dextrin/dextrates, maltodextrin, and compressible sugars. And mixtures of two or more above bulking agents or fillers can be used also. Mannitol is particularly suitable for use in the tablet of the present invention.
- disintegrants suitable for use herein include croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants.
- the disintegrant suitable for use in the tablet is croscarmellose sodium.
- binders suitable for use herein include hydroxypropyl cellulose, corn starch, dextrin, pregelatinized starch, modified corn starch, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, lactose, gum acacia, ethyl cellulose, cellulose acetate, polyethyleneglycol, as well as other conventional binding agents and/or mixtures of two or more thereof.
- the binder suitable for use herein is hydroxypropyl cellulose.
- the tablet according to the present invention contains the lubricants talc and sodium stearyl fumarate.
- furhter lubricants suitable for use herein include magnesium stearate, zinc stearate, calcium stearate, carnauba wax, stearic acid, palmitic acid, sodium laurel sulfate, glyceryl palrnitostearate, palmitic acid, myristic acid and hydrogenated vegetable oils and fats.
- surfactants suitable for use herein include phospholipid, glycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and sucrose fatty acid ester.
- flavors suitable for use herein include orange oil, fennel oil, cinnamon oil, clove oil, turpentine oil, peppermint oil, and eucalyptus oil.
- colorants suitable for use herein include carotinoids, iron oxides and chlorophylls.
- colorants also include Food Color Red Nos. 2 and 3, Food Color Yellow Nos. 4 and 5, Food Color Green No. 3, Food Color Blue Nos. 1 and 2, aluminum lakes of these Food Colors, iron sesquioxide, and yellow iron sesquioxide.
- sweetenings suitable for use herein include saccharine, and aspartame.
- the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof and b) one or more pharmaceutically acceptable additives.
- the active ingredient i.e., compound (A) or a pharmaceutically acceptable salt thereof
- the additives comprise a bulking agent (or a filler), a binder, a disintegrant, a lubricant, and optionally a coating agent.
- the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount within the range of from 65 % to 90% by weight of tablet; b) bulking agent (or filler) wherein the bulking agent or the filler is present in an amount within the range of from about 0 to 70 % by weight of tablet; c) binder, wherein the binder is present in an amount within the range of from about 1 to 25 % by weight of tablet; d) disintegrant, wherein the disintegrant is present in an amount within the range of from about 1 to 25 % by weight of tablet; and e) lubricant, wherein the lubricant is present in an amount within the range of from about 0.25 to 20 % by weight of tablet.
- the tablet comprises (a) compound (A) or a pharmaceutically acceptable salt thereof and (b) talc and sodium stearyl fumarate.
- the active ingredient i.e., compound (A) or a pharmaceutically acceptable salt thereof
- the tablet may further comprises additional pharmaceutically acceptable additives such as a bulking agent, a binder, a disintegrant, and optionally a coating agent.
- the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount within the range of from 65 % to 90% by weight of tablet; b) bulking agent (or filler), wherein the bulking agent or the filler is present in an amount within the range of from about 5 to 15 % by weight of tablet; c) binder, wherein the binder is present in an amount within the range of from about 1 to 5 % by weight of tablet; d) disintegrant, wherein the disintegrant is present in an amount within the range of from about 1 to 5 % by weight of tablet; and e) lubricant, wherein the lubricant is present in an amount within the range of from about 1 to 10 % by weight of tablet.
- the tablet comprises compound (A) or a pharmaceutically acceptable salt thereof in an amount within the range of 65% to 90% by weight of the tablet, preferably with the range of 65% to 75% by weight of the tablet.
- the tablet comprises the bulking agent or the filler in an amount less than 25% by weight of the tablet. In certain further preferred embodiments of the present invention, the tablet comprises the bulking agent or filler in an amount within the range of 5% to 20% by weight of the tablet, preferably 10% to 15% by weight of the tablet.
- the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount of 70 ⁇ 2% by weight of tablet; b) bulking agent (or filler), wherein the bulking agent or the filler is present in an amount of 12 ⁇ 2 % by weight of tablet; c) binder, wherein the binder is present in an amount of 3 ⁇ 1 % by weight of tablet; d) disintegrant, wherein the disintegrant is present in an amount of 4 ⁇ 1 % by weight of tablet; and e) lubricant, wherein the lubricant is present in an amount of 4 ⁇ 2 % by weight of tablet.
- the bulking agent is D-mannitol
- the binder is hydroxypropyl cellulose
- the disintegrant is croscarmellose sodium
- the lubricant is talc and sodium stearyl fumarate.
- the tablet further comprises a coating agent.
- the coating agent is present in an amount within the range of from about 0 to 25 %, more preferably 0 to 15 %, further more preferably 3 to 10 % by weight of the tablet.
- the tablet comprises a) compound (A) hemihydrate, wherein compound (A) hemihydrate is present in an amount of about 204 mg; b) D-mannitol, wherein D-mannitol is present in an amount of about 36 mg; c) hydroxypropyl cellulose, wherein hydroxypropyl cellulose is present in an amount of about 8 mg; d) croscarmellose sodium, wherein croscarmellose sodium is present in an amount of about 11.2 mg; e) talc, wherein talc is present in an amount of about 2.8 mg; and f) sodium stearyl fumarate, wherein sodium stearyl fumarate is present in an amount of about 8 mg.
- the tablet comprises a) compound (A) hemihydrate, wherein compound (A) hemihydrate is present In an amount of about 102 mg; b) D-mannitol, wherein D-mannitol Is present in an amount of about 18 mg; c) hydroxypropyl cellulose, wherein hydroxypropyl cellulose is present in an amount of about 4 mg; d) croscarmellose sodium, wherein croscarmellose sodium is present in an amount of about 5.6 mg; e) talc, wherein talc is present in an amount of about 1.4 mg; and f) sodium stearyl fumarate, wherein sodium stearyl fumarate is present in an amount of about 4 mg.
- the tablet comprises a) compound (A) hemihydrate, wherein compound (A) hemihydrate is present in an amount of about 51 mg; b) D-mannitol, wherein D-mannitol is present in an amount of about 9 mg; c) hydroxypropyl cellulose, wherein hydroxypropyl cellulose is present in an amount of about 2 mg; d) croscarmellose sodium, wherein croscarmellose sodium is present in an amount of about 2.8 mg; e) talc, wherein talc is present in an amount of about 0.7 mg; and f) sodium stearyl fumarate, wherein sodium stearyl fumarate is present in an amount of about 2 mg.
- the tablet of the present invention contains a high content of compound (A) or a pharmaceutically acceptable salt thereof given the relatively small amount of additives. This enables the production of physically small tablets.
- the tablets of the invention are, despite the high drug loading, small, and, therefore, convenient to administer. This leads to a better patient compliance.
- the tableting troubles such as binding, capping and sticking can be minimized and the ejection forces can be decreased during the tableting processes.
- the tablets of the present invention have superior characteristics. with respect to tablet hardness, friability and disintegration.
- the invention provides a tablet comprising from 25 mg to 600 mg of compound (A) or a pharmaceutically acceptable salt thereof, e.g., of from 50 mg to about 400 mg.
- the tablets according to the invention are tablets containing about 50 mg, tablets containing about 100 mg, tablets containing about 200 mg and/or tablets containing about 300 mg, of compound (A) or a pharmaceutically acceptable salt thereof.
- the tablet of the present invention can be prepared by the process comprising (a) forming granules comprising the compound (A) or a pharmaceutically acceptable salt thereof together with pharmaceutically acceptable additives, (b) mixing the obtained granules together with pharmaceutically acceptable extra additives, (c) forming the tablet by compressing the mixture obtained in step (b), and optionally (d) coating the tablet.
- the granules comprise compound (A) or a pharmaceutically acceptable salt thereof and one or more additives.
- the granules comprise compound (A) or a pharmaceutically acceptable salt thereof and one or more binders and bulking agents (or fillers).
- the amount of one or more binders in the granule is ranging from about 1 to 25 %, preferably 1 to 20 % and more preferably 1 to 15 % by weight of tablet.
- the amount of one or more bulking agents (or fillers) in the granule is ranging from about 0 to 70 %, preferably 0 to 60 % and more preferably 0 to 50 % by weight of tablet.
- the binders include hydroxypropyl cellulose.
- the amount of hydroxypropyl cellulose in the granule may vary from 1 to 15 %, preferably 1 to 10 % by weight of tablet.
- Preferable examples of the bulking agents (or fillers) include D-mannitol.
- the amount of D-mannitol in the granule may vary from about 0 to 70 %, in particular 0 to 50 % by weight of tablet.
- Granules can be prepared by methods well known to those skilled in the art. Examples of such methods include wet granulation, dry granulation, layering granulation, melt-granulation, and impregnated-granulation.
- compound (A) or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable additives are mixed together and the mixture is processed for granulation with water and/or binder solution using a wet high-shear granulator to form the wet-granulates.
- the wet-granulates may be then, dried using a fluid bed dryer.
- the tablets can be formed by mixing the granules with one or more extra additives (preferably, one or more disintegrants and one or more lubricants), and compressing the obtained mixture.
- one or more extra additives preferably, one or more disintegrants and one or more lubricants
- the preferable example of the disintegrants is croscarmellose sodium.
- the amount of disintegrant as an extra additive is ranging from about 1 to 25 %, more preferably 1 to 20 % by weight of tablet.
- the lubricants include talc and sodium stearyl fumarate.
- the amount of lubricants as an extra additive is ranging from about 0.25 to 20 %, more preferably 0.25 to 15 % by weight of tablet.
- the amount of talc is ranging from about 0.25 to 10 %, more preferably, 0.25 to 5 % by weight of tablet
- the amount of sodium stearyl fumarate is ranging from about 0.25 to 10 %, more preferably, 0.25 to 5 % by weight of tablet.
- the tablets are formed by compressing the mixture of the granules and extra additives.
- the compression can be conducted using a conventional tableting machine such as rotary tableting machine, single punch tableting machine, and the like, with a compressing pressure of generally about from 1 to 30 KN.
- the tablets may be coated with the aim of, for example, preventing abrasion wear, masking bitterness, improving stability.
- the coating can be carried out in a conventional manner; however, it is preferable to confine the coating amount to such an extent that does not disturb the dissolution of compound (A) or a pharmaceutically acceptable salt thereof.
- the amount of the coating layer of the tablet, where present is ranging from about 0 % to about 25 % by weight of tablet, more preferably, 0% to 15 % by weight of tablet.
- Suitable examples of polymer for the coating include hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, and starch.
- the coating layer can also optionally include an anti- adherent or glidant such as fumed silica, or magnesium stearate, for example.
- the coating layer can also optionally include an opacifying agent such as titanium dioxide, and a colorant such as iron oxide based colorant(s). Examples of commercially available coating agent include Opadry® HP and Opadry® II.
- the tablet may vary in shape and be, for example, round, oval, or any other suitable shape.
- a characteristic of tablets according to the invention is their small size having regard to the amount of compound (A) or a pharmaceutically acceptable salt thereof.
- tablets obtained by the compression methods described above are round or oval.
- the round tablet may be of the following dimensions, e.g., 3 to 14 mm in diameter, preferably 5 to 12 mm.
- the thickness of the tablet may be from 1.5 to 7 mm, preferably 2.5 to 6 mm.
- the tablets of the invention may furthermore be colored.
- Colorants suitable for use herein include carotinoids, iron oxides or chlorophyll.
- the tablet is chosen to exhibit immediate release of compound (A) or a pharmaceutically acceptable salt thereof, e.g., compound (A) hemihydrate.
- Procedures which may be used may be conventional or known in the art or based on such procedures, e.g., those described in Remington's Pharmaceutical Sciences.
- the dose of the tablet of the invention for any particular patient will depend upon a variety of factors including the age, the body weight, general health, drug combination with one or more active drugs, type and severity of the disease.
- the tablet of the present invention can be optionally administered to a patient in need of treatments in combination with one or more other therapeutic agents such as other anti-diabetic agents, anti-hyper glycemic agents and/or agents for treatment of other diseases.
- one or more other therapeutic agents such as other anti-diabetic agents, anti-hyper glycemic agents and/or agents for treatment of other diseases.
- Examples of the other anti-diabetic agents and anti-hyper glycemic agents include insulin, insulin secretagogues, insulin sensitizers, or other antidiabetic agents having an action mechanism different from SGLT inhibition.
- these agents are biguanides, sulfonylureas, ⁇ -glucosidase inhibitors, PPAR ⁇ agonists (e.g., thiazolidinedione compounds), PPAR ⁇ / ⁇ dual agonists, PPARpan agonists, dipeptidyl peptidase IV (DPP4) inhibitors, mitiglinide, nateglinide, repaglinide, insulin, glucagon-like peptide-1 (GLP-1) and its receptor agonists, PTP1B inhibitors, glycogen phosphorylase inhibitors, RXR modulators, glucose 6-phosphatase inhibitors, GPR40 agonists/antagonists, GPR119 agonists, GPR120 agonists, glucokina
- agents for treatment of other diseases include anti-obesity agents, anti-hypertensive agents, anti-platelet agents, anti-atherosclerotic agents and hypolipidemic agents.
- anti-obesity agents which may be optionally employed in combination with the compound of the present invention include ⁇ 3 adrenergic agonists, lipase inhibitors, serotonin (and dopamine) reuptake inhibitors, thyroid hormone receptor beta drugs, anorectic agents, NPY antagonists, Leptin analogs, MC4 agonists and CB1 antagonists.
- anti-platelet agents which may be optionally employed in combination with the compound of the present invention include abciximab, ticlopidine, eptifibatide, dipyridamole, aspirin, anagrelide, tirofiban and clopidogrel.
- anti-hypertensive agents which may be optionally employed in combination with the compound of the present invention include ACE inhibitors, calcium antagonists, alpha-blockers, diuretics, centrally acting agents, angiotensin-II antagonists, beta-blockers, renin inhibitors and vasopeptidase inhibitors.
- hypolipidemic agents which may be optionally employed in combination with the compound of the present invention include MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, squalene epoxidase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na+/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, nicotinic acid and derivatives thereof, CETP inhibitors, and ABC A1 upregulators.
- the dosage of those agents may vary according to ages, body weight, conditions of patients, administration routes, and dosage forms.
- each of the compounds of the combination can be administered simultaneously or sequentially and in any order, in jointly therapeutically effective amounts.
- the 1-( ⁇ -D-glucopyranosyl)-3-(phenylthienylmethyl)benzene derivative of formula (A) can be prepared, for example, by a process as described in WO 2005/012326 .
- compound (A) hemihydrate can be prepared by a process described in WO 2008/069327 .
- Compound (A) may be referred to as 1-( ⁇ -D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl]benzene or (1 S )-1,5-anhydro-1-(3- ⁇ [5-(4-fluorophenyl)-2-thienyl]methyl ⁇ -4-methylphenyl)-D-glucitol, depending on the nomenclature.
- 1- ⁇ -D-glucopyranosyl-substituted phenylthienylmethyl benzene derivative of formula (A) can be prepared in a process comprising the steps of:
- the coupling reaction is typically carried out in tetrahydrofuran at lower or ambient temperature.
- the resulting compound is typically treated with methanesulfonic acid in methanol to give the compound of formula (IV).
- the acetylation can be carried out with acetyl anhydride in a suitable solvent such as toluene and ethyl acetate in the presence of a base such as N-methylmorpholine and 4-dimethylaminopyridine at lower or ambient temperature.
- a suitable solvent such as toluene and ethyl acetate
- a base such as N-methylmorpholine and 4-dimethylaminopyridine at lower or ambient temperature.
- the reduction is typically carried out by treating the compound of formula (III) with a reducing agent, such as triethylsilyl hydride and a Lewis acid, such as BF 3 .Et 2 O, in a suitable solvent such as CH 3 CN, and water.
- a reducing agent such as triethylsilyl hydride and a Lewis acid, such as BF 3 .Et 2 O
- the hydrolysis is typically carried out by treating the compound of formula (II) with a base such as lithium hydroxide in a suitable solvent such as methanol, tetrahydrofuran and water.
- a base such as lithium hydroxide
- a suitable solvent such as methanol, tetrahydrofuran and water.
- Compound (A) is typically treated with water-containing solvent to form a crystal slurry of a hemihydrate thereof and separating out a hemihydrate thereof.
- the activity of compound (A) or a pharmaceutically acceptable salt thereof can be determined using, for example, the assay system described in US 2005/0233988 A1 or any appropriate assay system known in the art.
- Table 1 shows the components and compositions of the tablets.
- the tablets were prepared in accordance with the method described below.
- Table 1 Composition of Drug Product Component Function mg/tablet % w/w Quantity/Batch(g) ⁇ Intra-granular Additions> Compound (A) Drug Substance 204.0 * 71.33 4080 D-Mannitol Filler 36.0 12.59 720 Hydroxypropyl Cellulose Binder 8.0 2.80 160 Purified Water Processing Aqent * * * * * * * * * * * * * * * ⁇ Extra-qranular Additions> Croscarmellose Sodium Disintegrant 11.2 3.92 224 Talc Lubricant 2.8 0.98 56 Sodium Stearyl Fumarate Lubricant 8.0 2.80 160 Core Totals 270.0 94.4 5400 Opadry II *** Coating Aqent 16.0 5.59 320 Purified Water Processing Agent * * * * * * Totals 286.0 100.0 5720 *Amount of hemihydrate, equivalent to 200 mg anhydrous form of drug
- Compound (A) D-mannitol and hydroxypropyl cellulose were blended in High Shear Mixer (High Speed Mixer; FS-GS-25J, Fukae Powtex Co., Osaka, Japan) for one minute. The mix was granulated adding purified water. After the completion of adding water, the granulation was continued for two minutes.
- High Shear Mixer High Speed Mixer; FS-GS-25J, Fukae Powtex Co., Osaka, Japan
- the wet granules were set in fluidized bed drier (Flow Coater; FLO-5M, Freund Co., Tokyo, Japan) and dried. During the drying, the samples of granules were taken from the fluidized bed drier at certain intervals. The moisture level during drying was determined to measure the loss on drying (LOD) of the sample.
- fluidized bed drier Flow Coater; FLO-5M, Freund Co., Tokyo, Japan
- the dried granules were sized with a 22 mesh (710 ⁇ m) sieve.
- the granules of oversized fraction were crushed by using New Speed Mill (ND-10S, Okada Seiko Co. Ltd., Tokyo, Japan) with 2.5 mm and 1.0 mm circular holes screen, followed by passing through a 22 mesh sieve completely.
- Extra-granular Additions (croscarmellose sodium, talc and sodium stearyl fumarate) were premixed with a portion of sized granules in a plastic bag and passed through a 22 mesh (710 ⁇ m) sieve respectively. These premixed powders and the residual sized granules were blended for 4 minutes in a V type Blender (SVM-50, Meiwa Kougyo Co., Nagoya, Japan).
- V type Blender SVM-50, Meiwa Kougyo Co., Nagoya, Japan
- the final blend was compressed into tablets using a rotary press (VIRGO0518SS2AZ, Kikusui Seisakusyo Ltd., Kyoto, Japan) equipped with round biconvex punches of 9 mm in diameter. Tablets were compressed at varying compression forces from 4.2 KN to 6.5 KN. The coefficient of variation in tablet weight was less than 1.0 % and the friability of tablet was less than 0.2 %. Tablet hardness was increased from 67 N to 99 N and the corresponding tablet thickness was decreased from 4.54 mm to 4.35 mm. These results show the good compressibility and compactibility of the final blend.
- In vitro drug release was measured using the Japanese Pharmacopoeia XV(JP XV) apparatus II fitted with paddles rotated at 75 rpm.
- Dissolution medium was used phosphate buffer pH 6.8 (2nd fluid in JP XV) containing 0.1 % w/w polysorbate 80.
- a dissolved amount of Compound (A) was between about 90 % and 94 % at 30 minutes. The dissolution rate was not affected by compression force.
- the compressed tablets were coated in aqueous film coating system using Opadry II 15 % solid content suspension based on polyvinyl alcohol. Tablet coating was carried out in a conventional coating pan (Doria coater, DRC-500, Powrex Co., Hyougo, Japan) using spray coating technique and conducted under a generalized manufacturing condition. The tablets were coated without any problem and the prepared tablets were free from defects such as picking and peeling.
- Tablets containing 102 mg of compound (A) hemihydrate (which corresponds to 100 mg of compound (A)) were prepared in accordance with the method described in Example 1. Components and compositions of the tablets are described in Table 2. Table 2. Composition of Tablet Component mg/tablet Compound (A) 102.0 * D-Mannitol 18.0 Hydroxypropyl Cellulose 4.0 Croscarmellose Sodium 5.6 Talc 1.4 Sodium Stearyl Fumarate 4.0 Opadry II 10.0 * Amount of hemihydrate, equivalent to 100 mg of anhydrous compound (A)
- Tablets containing 51 mg of compound (A) hemihydrate were prepared in accordance with the method described in Example 1. Components and compositions of the tablet are described in Table 3. Table 3. Composition of Tablet Component mg/tablet Compound (A) 51.0 * D-Mannitol 9.0 Hydroxypropyl Cellulose 2.0 Croscarmellose Sodium 2.8 Talc 0.7 Sodium Stearyl Fumarate 2.0 Opadry II 5.5 * Amount of hemihydrate, equivalent to 50 mg of anhydrous compound (A)
- Tablets containing 306 mg of compound (A) hemihydrate (which corresponds to 300 mg of compound (A)) were prepared in accordance with the method described below. Components and compositions of the tablets are described in Table 4. Table 4. Composition of Tablet Component mg/tablet Compound (A) 306.0 * D-Mannitol 54.0 Hydroxypropyl Cellulose 12.0 Croscarmellose Sodium 16.8 Talc 4.2 Sodium Stearyl Fumarate 12.0 * Amount of hemihydrate, equivalent to 300 mg of anhydrous compound (A)
- Compound (A) D-mannitol and hydroxypropyl cellulose were blended in High Shear Mixer (Virtical Granulator; VG-100, Powrex Co., Hyogo, Japan) for one minute. The mix was granulated adding purified water. After the completion of adding water, the granulation was continued for two minutes.
- High Shear Mixer Virtual Granulator; VG-100, Powrex Co., Hyogo, Japan
- the wet granules were crushed by using New Speed Mill (ND-10S, Okada Seiko Co. Ltd., Tokyo, Japan) with 5.0 mm circular holes screen, and were set in fluidized bed drier (Flow Coater; NFLO-30SJ, Freund Co., Tokyo, Japan) and dried.
- New Speed Mill N-10S, Okada Seiko Co. Ltd., Tokyo, Japan
- fluidized bed drier Flow Coater; NFLO-30SJ, Freund Co., Tokyo, Japan
- the dried granules were sized with a 22 mesh (710 ⁇ m) sieve.
- the granules of oversized fraction were crushed by using New Speed Mill (ND-10S, Okada Seiko Co. Ltd., Tokyo, Japan) with 5.0 mm, 2.5 mm and 1.0 mm circular holes screen, followed by passing through a 22 mesh sieve completely.
- the sized granules were set in fluidized bed drier (Flow Coater; NFLO-30SJ, Freund Co., Tokyo, Japan) and dried once again.
- fluidized bed drier Flow Coater; NFLO-30SJ, Freund Co., Tokyo, Japan
- the samples of granules were taken from the fluidized bed drier at certain intervals.
- the moisture level during drying was determined to measure the loss on drying (LOD) of the sample.
- Extra-granular additions (croscarmellose sodium, talc and sodium stearyl fumarate) were premixed with a portion of sized granules in a plastic bag and passed through a 22 mesh (710 ⁇ m) sieve respectively. These premixed powders and the residual sized granules were blended for 4 minutes in a W type Blender (W-60, Tokujyu Kousakusyo Co., Kanagawa, Japan).
- W-60 Tokujyu Kousakusyo Co., Kanagawa, Japan
- the final blend was compressed into tablets using a single punch press (Compaction Analyzer, Kikusui Seisakusyo Ltd., Kyoto, Japan) equipped with oval shaped punch (major axis:13.5 mm, minor axis:7.70 mm). Tablets were compressed at varying compression forces from 4.2 KN to 5.4 KN. Tablet hardness was increased from 99 N to 121 N and the corresponding tablet thickness was decreased from 5.12 mm to 5.00 mm. These results show the good compressibility and compactibility of the final blend. Additionally, In vitro drug release was measured using the Japanese Pharmacopoeia XV(JP XV) apparatus II fitted with paddles rotated at 50 rpm.
- Dissolution medium was used phosphate buffer pH 6.8 (2nd fluid in JP XV) containing 0.1 % w/w polysorbate 80. A dissolved amount of Compound A was between about 77 % and 82 % at 60 minutes. The dissolution rate was not affected by compression force.
- Tablets were prepared in accordance with the method described below, where the components and compositions of the tablets are described in Table 5.
- Compound (A) D-mannitol and hydroxypropyl cellulose were blended in High Shear Mixer (High Speed Mixer; LFS-GS-1, Fukae Powtex Co., Osaka, Japan). The mix was granulated adding purified water. After the completion of adding water, the granulation was continued.
- High Shear Mixer High Speed Mixer; LFS-GS-1, Fukae Powtex Co., Osaka, Japan
- the wet granules were set in fluidized bed drier (Multiplex; MP-01/03, Powrex Co., Hyougo, Japan) and dried until the product temperature reaches 40 °C.
- fluidized bed drier Multiplex; MP-01/03, Powrex Co., Hyougo, Japan
- the dried granules were sized with a 22 mesh (710 ⁇ m) sieve.
- the granules of oversized fraction were crushed by using Power Mill (P-02S, Dalton Co. Ltd., Tokyo, Japan) with 2 mm herringbone screen and 1.0 mm circular holes screen, followed by passing through a 22 mesh sieve completely.
- Extra-granular additions (croscarmellose sodium, magnesium stearate, talc and sodium stearyl fumarate) were passed through a 42 mesh (355 ⁇ m) sieve. These powders and sized granules were put in a plastic bag and mixed 50 times
- n-Heptane (5.6 mL) was added to the mixture at 40 °C, then the mixture was seeded with a slight amount of (1 S )-1,5-anhydro-1-(3- ⁇ [5-(4-fluorophenyl)-2-thienyl]methyl ⁇ -4- methylphenyl)-D-glucitol at same temperature. After stirred for 1 hour at 35°C, n-heptane (2.6 mL) was added slowly to the mixture. The resulting mixture was cooled.
Description
- The present invention relates to a tablet containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene derivative or a pharmaceutically acceptable salt thereof that can be used in the treatment of diabetes mellitus, obesity, diabetic complications, and the related diseases.
-
WO 2009/022010 A1 relates to a pharmaceutical composition comprising a SGLT2 inhibitor in combination with a dipeptidyl peptidase -IV (DPP-IV) inhibitor. -
WO 2005/012326 pamphlet discloses a class of compounds that are inhibitors of sodium-dependent glucose transporter (SGLT) and thus of therapeutic use for treatment of diabetes, obesity, diabetic complications, and the like.WO 2005/012326 pamphlet describes 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene having the following formula: - Compound (A) hemihydrate and a certain crystal form thereof are disclosed in International Patent Application
WO 2008/069327 . -
- The pharmaceutically acceptable salts of compound (A) include, for example, a salt with an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or a salt with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, etc.; or a salt with an acidic amino acid such as aspartic acid, glutamic acid, etc.
- In addition, pharmaceutically acceptable salts of the compound of formula (A) include an intramolecular salt, hydrate, solvate or polymorphism thereof. Preferably, a pharmaceutically acceptable salt of compound (A) is hemihydrate.
- Compound (A) is also known as canagliflozin.
- The active pharmaceutical ingredient, i.e., compound (A) or a pharmaceutically acceptable salt thereof, possesses activity as an inhibitor of the sodium dependent glucose transporters found in the intestine and kidney, and therefore the tablet of the present invention can be used in the treatment or prevention of patients, such as human patients, for diseases or disorders associated with SGLT activity. Thus, the tablet of the present invention can be used for the treatment, prevention or delaying the progression or onset of diabetes mellitus (such as type 1 and type 2 diabetes mellitus), diabetic complications (such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, atherosclerosis, or hypertension.
- In one embodiment, the invention relates to a tablet as defined in the appended claims in the treatment or delaying the progression or onset of type II diabetes mellitus or obesity.
- In another embodiment, the invention relates to the tablet as defined in the appended claims for use in treating or delaying the progression or onset of diseases associated with SGLT activity.
- In another embodiment, the invention relates to the tablet as defined in the appended claims for use in treating or delaying the progression or onset of type II diabetes mellitus or obesity.
- The tablet of the present invention may contain additives generally used in pharmaceutical solid tablets. Examples of the additives include bulking agents (or fillers), disintegrants, binders, lubricants, coating agents, surfactants, flavors, colorants and sweetenings.
- Examples of the bulking agents or fillers suitable for use herein include lactose, sucrose, mannitol, xylitol, erythritol, sorbitol, maltitol, calcium citrate, calcium phosphate, and calcium aluminometasilicate. Examples of the bulking agents or fillers also include cellulose derivatives, such as microcrystalline cellulose or wood cellulose, lactose, sucrose, starch, pregelatinized starch, dextrose, mannitol, fructose, xylitol, sorbitol, corn starch, modified corn starch, inorganic salts such as calcium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, dextrin/dextrates, maltodextrin, and compressible sugars. And mixtures of two or more above bulking agents or fillers can be used also. Mannitol is particularly suitable for use in the tablet of the present invention.
- Examples of disintegrants suitable for use herein include croscarmellose sodium, crospovidone, starch, potato starch, pregelatinized starch, corn starch, sodium starch glycolate, microcrystalline cellulose, low substituted hydroxypropyl cellulose and other known disintegrants. Preferably, the disintegrant suitable for use in the tablet is croscarmellose sodium.
- Examples of binders suitable for use herein include hydroxypropyl cellulose, corn starch, dextrin, pregelatinized starch, modified corn starch, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, lactose, gum acacia, ethyl cellulose, cellulose acetate, polyethyleneglycol, as well as other conventional binding agents and/or mixtures of two or more thereof. Preferably, the binder suitable for use herein is hydroxypropyl cellulose.
The tablet according to the present invention contains the lubricants talc and sodium stearyl fumarate. Examples of furhter lubricants suitable for use herein include magnesium stearate, zinc stearate, calcium stearate, carnauba wax, stearic acid, palmitic acid, sodium laurel sulfate, glyceryl palrnitostearate, palmitic acid, myristic acid and hydrogenated vegetable oils and fats. - Examples of surfactants suitable for use herein include phospholipid, glycerin fatty acid ester, sorbitan fatty acid ester, polyoxyethylene fatty acid ester, polyethylene glycol fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene alkyl ether, and sucrose fatty acid ester.
- Examples of flavors suitable for use herein include orange oil, fennel oil, cinnamon oil, clove oil, turpentine oil, peppermint oil, and eucalyptus oil.
- Examples of colorants suitable for use herein include carotinoids, iron oxides and chlorophylls. Examples of colorants also include Food Color Red Nos. 2 and 3, Food Color Yellow Nos. 4 and 5, Food Color Green No. 3, Food Color Blue Nos. 1 and 2, aluminum lakes of these Food Colors, iron sesquioxide, and yellow iron sesquioxide.
- Examples of sweetenings suitable for use herein include saccharine, and aspartame.
- According to the present invention, the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof and b) one or more pharmaceutically acceptable additives. The active ingredient (i.e., compound (A) or a pharmaceutically acceptable salt thereof) is in an amount within the range of from 65 % to 90% by weight of tablet. Preferably, the additives comprise a bulking agent (or a filler), a binder, a disintegrant, a lubricant, and optionally a coating agent.
- In another embodiment of the present invention, the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount within the range of from 65 % to 90% by weight of tablet; b) bulking agent (or filler) wherein the bulking agent or the filler is present in an amount within the range of from about 0 to 70 % by weight of tablet; c) binder, wherein the binder is present in an amount within the range of from about 1 to 25 % by weight of tablet; d) disintegrant, wherein the disintegrant is present in an amount within the range of from about 1 to 25 % by weight of tablet; and e) lubricant, wherein the lubricant is present in an amount within the range of from about 0.25 to 20 % by weight of tablet.
- In a preferable embodiment, the tablet comprises (a) compound (A) or a pharmaceutically acceptable salt thereof and (b) talc and sodium stearyl fumarate. In this embodiment, the active ingredient (i.e., compound (A) or a pharmaceutically acceptable salt thereof) is preferably in an amount within the range of from 65 % to 90% by weight of tablet. The tablet may further comprises additional pharmaceutically acceptable additives such as a bulking agent, a binder, a disintegrant, and optionally a coating agent.
- In another preferable embodiment of the present invention, the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount within the range of from 65 % to 90% by weight of tablet; b) bulking agent (or filler), wherein the bulking agent or the filler is present in an amount within the range of from about 5 to 15 % by weight of tablet; c) binder, wherein the binder is present in an amount within the range of from about 1 to 5 % by weight of tablet; d) disintegrant, wherein the disintegrant is present in an amount within the range of from about 1 to 5 % by weight of tablet; and e) lubricant, wherein the lubricant is present in an amount within the range of from about 1 to 10 % by weight of tablet.
- In the present invention, the tablet comprises compound (A) or a pharmaceutically acceptable salt thereof in an amount within the range of 65% to 90% by weight of the tablet, preferably with the range of 65% to 75% by weight of the tablet.
- In certain preferred embodiments of the present invention, the tablet comprises the bulking agent or the filler in an amount less than 25% by weight of the tablet. In certain further preferred embodiments of the present invention, the tablet comprises the bulking agent or filler in an amount within the range of 5% to 20% by weight of the tablet, preferably 10% to 15% by weight of the tablet.
- In another preferable embodiment of the present invention, the tablet comprises a) compound (A) or a pharmaceutically acceptable salt thereof, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount of 70 ± 2% by weight of tablet; b) bulking agent (or filler), wherein the bulking agent or the filler is present in an amount of 12 ± 2 % by weight of tablet; c) binder, wherein the binder is present in an amount of 3 ± 1 % by weight of tablet; d) disintegrant, wherein the disintegrant is present in an amount of 4 ± 1 % by weight of tablet; and e) lubricant, wherein the lubricant is present in an amount of 4 ± 2 % by weight of tablet.
- Preferably, the bulking agent is D-mannitol, the binder is hydroxypropyl cellulose, the disintegrant is croscarmellose sodium, the lubricant is talc and sodium stearyl fumarate.
- In a more preferable embodiment of the invention, the tablet further comprises a coating agent. The coating agent is present in an amount within the range of from about 0 to 25 %, more preferably 0 to 15 %, further more preferably 3 to 10 % by weight of the tablet.
- In a more preferable embodiment of the present invention, the tablet comprises a) compound (A) hemihydrate, wherein compound (A) hemihydrate is present in an amount of about 204 mg; b) D-mannitol, wherein D-mannitol is present in an amount of about 36 mg; c) hydroxypropyl cellulose, wherein hydroxypropyl cellulose is present in an amount of about 8 mg; d) croscarmellose sodium, wherein croscarmellose sodium is present in an amount of about 11.2 mg; e) talc, wherein talc is present in an amount of about 2.8 mg; and f) sodium stearyl fumarate, wherein sodium stearyl fumarate is present in an amount of about 8 mg.
- In another more preferable embodiment of the present invention, the tablet comprises a) compound (A) hemihydrate, wherein compound (A) hemihydrate is present In an amount of about 102 mg; b) D-mannitol, wherein D-mannitol Is present in an amount of about 18 mg; c) hydroxypropyl cellulose, wherein hydroxypropyl cellulose is present in an amount of about 4 mg; d) croscarmellose sodium, wherein croscarmellose sodium is present in an amount of about 5.6 mg; e) talc, wherein talc is present in an amount of about 1.4 mg; and f) sodium stearyl fumarate, wherein sodium stearyl fumarate is present in an amount of about 4 mg.
- In another more preferable embodiment of the present invention, the tablet comprises a) compound (A) hemihydrate, wherein compound (A) hemihydrate is present in an amount of about 51 mg; b) D-mannitol, wherein D-mannitol is present in an amount of about 9 mg; c) hydroxypropyl cellulose, wherein hydroxypropyl cellulose is present in an amount of about 2 mg; d) croscarmellose sodium, wherein croscarmellose sodium is present in an amount of about 2.8 mg; e) talc, wherein talc is present in an amount of about 0.7 mg; and f) sodium stearyl fumarate, wherein sodium stearyl fumarate is present in an amount of about 2 mg.
- It is a characteristic of the tablet of the present invention that it contains a high content of compound (A) or a pharmaceutically acceptable salt thereof given the relatively small amount of additives. This enables the production of physically small tablets. The tablets of the invention are, despite the high drug loading, small, and, therefore, convenient to administer. This leads to a better patient compliance.
- Also, according to the present invention, due to the remarkable increase in compactibllity of granules for tableting, the tableting troubles such as binding, capping and sticking can be minimized and the ejection forces can be decreased during the tableting processes. In addition, the tablets of the present invention have superior characteristics. with respect to tablet hardness, friability and disintegration.
- In another embodiment, the invention provides a tablet comprising from 25 mg to 600 mg of compound (A) or a pharmaceutically acceptable salt thereof, e.g., of from 50 mg to about 400 mg. Most preferably, the tablets according to the invention are tablets containing about 50 mg, tablets containing about 100 mg, tablets containing about 200 mg and/or tablets containing about 300 mg, of compound (A) or a pharmaceutically acceptable salt thereof.
- The tablet of the present invention can be prepared by the process comprising (a) forming granules comprising the compound (A) or a pharmaceutically acceptable salt thereof together with pharmaceutically acceptable additives, (b) mixing the obtained granules together with pharmaceutically acceptable extra additives, (c) forming the tablet by compressing the mixture obtained in step (b), and optionally (d) coating the tablet.
- The granules comprise compound (A) or a pharmaceutically acceptable salt thereof and one or more additives. Preferably, the granules comprise compound (A) or a pharmaceutically acceptable salt thereof and one or more binders and bulking agents (or fillers). The amount of one or more binders in the granule is ranging from about 1 to 25 %, preferably 1 to 20 % and more preferably 1 to 15 % by weight of tablet. The amount of one or more bulking agents (or fillers) in the granule is ranging from about 0 to 70 %, preferably 0 to 60 % and more preferably 0 to 50 % by weight of tablet. Preferable examples of the binders include hydroxypropyl cellulose. The amount of hydroxypropyl cellulose in the granule may vary from 1 to 15 %, preferably 1 to 10 % by weight of tablet. Preferable examples of the bulking agents (or fillers) include D-mannitol. The amount of D-mannitol in the granule may vary from about 0 to 70 %, in particular 0 to 50 % by weight of tablet.
- Granules can be prepared by methods well known to those skilled in the art. Examples of such methods include wet granulation, dry granulation, layering granulation, melt-granulation, and impregnated-granulation.
- For example, compound (A) or a pharmaceutically acceptable salt thereof and the pharmaceutically acceptable additives are mixed together and the mixture is processed for granulation with water and/or binder solution using a wet high-shear granulator to form the wet-granulates. The wet-granulates may be then, dried using a fluid bed dryer.
- The tablets can be formed by mixing the granules with one or more extra additives (preferably, one or more disintegrants and one or more lubricants), and compressing the obtained mixture. The preferable example of the disintegrants is croscarmellose sodium. The amount of disintegrant as an extra additive is ranging from about 1 to 25 %, more preferably 1 to 20 % by weight of tablet.
- The lubricants include talc and sodium stearyl fumarate. Preferably, the amount of lubricants as an extra additive is ranging from about 0.25 to 20 %, more preferably 0.25 to 15 % by weight of tablet. Most preferably, the amount of talc is ranging from about 0.25 to 10 %, more preferably, 0.25 to 5 % by weight of tablet, and the amount of sodium stearyl fumarate is ranging from about 0.25 to 10 %, more preferably, 0.25 to 5 % by weight of tablet.
- According to the invention, the tablets are formed by compressing the mixture of the granules and extra additives. The compression can be conducted using a conventional tableting machine such as rotary tableting machine, single punch tableting machine, and the like, with a compressing pressure of generally about from 1 to 30 KN.
- Optionally, the tablets may be coated with the aim of, for example, preventing abrasion wear, masking bitterness, improving stability. The coating can be carried out in a conventional manner; however, it is preferable to confine the coating amount to such an extent that does not disturb the dissolution of compound (A) or a pharmaceutically acceptable salt thereof.
- Preferably, the amount of the coating layer of the tablet, where present, is ranging from about 0 % to about 25 % by weight of tablet, more preferably, 0% to 15 % by weight of tablet.
- Suitable examples of polymer for the coating include hydroxypropyl methylcellulose, polyvinyl alcohol, ethyl cellulose, methacrylic polymers, hydroxypropyl cellulose, and starch. The coating layer can also optionally include an anti- adherent or glidant such as fumed silica, or magnesium stearate, for example. The coating layer can also optionally include an opacifying agent such as titanium dioxide, and a colorant such as iron oxide based colorant(s). Examples of commercially available coating agent include Opadry® HP and Opadry® II.
- The tablet may vary in shape and be, for example, round, oval, or any other suitable shape. A characteristic of tablets according to the invention is their small size having regard to the amount of compound (A) or a pharmaceutically acceptable salt thereof.
- In a preferred embodiment of the invention tablets obtained by the compression methods described above are round or oval. For example, the round tablet may be of the following dimensions, e.g., 3 to 14 mm in diameter, preferably 5 to 12 mm. The thickness of the tablet may be from 1.5 to 7 mm, preferably 2.5 to 6 mm.
- The tablets of the invention may furthermore be colored. Colorants suitable for use herein include carotinoids, iron oxides or chlorophyll.
- Preferably the tablet is chosen to exhibit immediate release of compound (A) or a pharmaceutically acceptable salt thereof, e.g., compound (A) hemihydrate.
- Procedures which may be used may be conventional or known in the art or based on such procedures, e.g., those described in Remington's Pharmaceutical Sciences.
- It will be understood that the dose of the tablet of the invention for any particular patient will depend upon a variety of factors including the age, the body weight, general health, drug combination with one or more active drugs, type and severity of the disease.
- The tablet of the present invention can be optionally administered to a patient in need of treatments in combination with one or more other therapeutic agents such as other anti-diabetic agents, anti-hyper glycemic agents and/or agents for treatment of other diseases.
- Examples of the other anti-diabetic agents and anti-hyper glycemic agents include insulin, insulin secretagogues, insulin sensitizers, or other antidiabetic agents having an action mechanism different from SGLT inhibition. Specifically, examples of these agents are biguanides, sulfonylureas, α-glucosidase inhibitors, PPARγ agonists (e.g., thiazolidinedione compounds), PPARα/γ dual agonists, PPARpan agonists, dipeptidyl peptidase IV (DPP4) inhibitors, mitiglinide, nateglinide, repaglinide, insulin, glucagon-like peptide-1 (GLP-1) and its receptor agonists, PTP1B inhibitors, glycogen phosphorylase inhibitors, RXR modulators, glucose 6-phosphatase inhibitors, GPR40 agonists/antagonists, GPR119 agonists, GPR120 agonists, glucokinase (GK) activators, and fructose 1,6-bisphosphatase (FBPase) inhibitors.
- Examples of the agents for treatment of other diseases include anti-obesity agents, anti-hypertensive agents, anti-platelet agents, anti-atherosclerotic agents and hypolipidemic agents.
- The anti-obesity agents which may be optionally employed in combination with the compound of the present invention include β3 adrenergic agonists, lipase inhibitors, serotonin (and dopamine) reuptake inhibitors, thyroid hormone receptor beta drugs, anorectic agents, NPY antagonists, Leptin analogs, MC4 agonists and CB1 antagonists.
- The anti-platelet agents which may be optionally employed in combination with the compound of the present invention include abciximab, ticlopidine, eptifibatide, dipyridamole, aspirin, anagrelide, tirofiban and clopidogrel.
- The anti-hypertensive agents which may be optionally employed in combination with the compound of the present invention include ACE inhibitors, calcium antagonists, alpha-blockers, diuretics, centrally acting agents, angiotensin-II antagonists, beta-blockers, renin inhibitors and vasopeptidase inhibitors.
- The hypolipidemic agents which may be optionally employed in combination with the compound of the present invention include MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, squalene epoxidase inhibitors, fibric acid derivatives, ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na+/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, bile acid sequestrants, nicotinic acid and derivatives thereof, CETP inhibitors, and ABC A1 upregulators.
- The dosage of those agents may vary according to ages, body weight, conditions of patients, administration routes, and dosage forms.
- Where the tablet of the present invention is used in combination with other therapeutic agent(s), each of the compounds of the combination can be administered simultaneously or sequentially and in any order, in jointly therapeutically effective amounts.
- The 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene derivative of formula (A) can be prepared, for example, by a process as described in
WO 2005/012326 . And compound (A) hemihydrate can be prepared by a process described inWO 2008/069327 . Compound (A) may be referred to as 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl]benzene or (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol, depending on the nomenclature. - In another example, 1-β-D-glucopyranosyl-substituted phenylthienylmethyl benzene derivative of formula (A) can be prepared in a process comprising the steps of:
- (a) coupling a compound of formula (V) with a compound of formula (VI) and treating the resulting compound with methanesulfonic acid:
- (b) acetylating the compound of formula (IV):
- (d) reducing the compound of formula (III):
- and, (e) hydrolyzing the compound of formula (II):
- The coupling reaction is typically carried out in tetrahydrofuran at lower or ambient temperature. The resulting compound is typically treated with methanesulfonic acid in methanol to give the compound of formula (IV).
- The acetylation can be carried out with acetyl anhydride in a suitable solvent such as toluene and ethyl acetate in the presence of a base such as N-methylmorpholine and 4-dimethylaminopyridine at lower or ambient temperature.
- The reduction is typically carried out by treating the compound of formula (III) with a reducing agent, such as triethylsilyl hydride and a Lewis acid, such as BF3.Et2O, in a suitable solvent such as CH3CN, and water.
- The hydrolysis is typically carried out by treating the compound of formula (II) with a base such as lithium hydroxide in a suitable solvent such as methanol, tetrahydrofuran and water.
- Compound (A) is typically treated with water-containing solvent to form a crystal slurry of a hemihydrate thereof and separating out a hemihydrate thereof.
- The activity of compound (A) or a pharmaceutically acceptable salt thereof can be determined using, for example, the assay system described in
US 2005/0233988 A1 or any appropriate assay system known in the art. - The following examples are provided to describe the invention in further detail. These examples are intended to illustrate and not to limit the invention.
- Table 1 shows the components and compositions of the tablets. The tablets were prepared in accordance with the method described below.
Table 1. Composition of Drug Product Component Function mg/tablet % w/w Quantity/Batch(g) <Intra-granular Additions> Compound (A) Drug Substance 204.0 * 71.33 4080 D-Mannitol Filler 36.0 12.59 720 Hydroxypropyl Cellulose Binder 8.0 2.80 160 Purified Water Processing Aqent * * * * * * <Extra-qranular Additions> Croscarmellose Sodium Disintegrant 11.2 3.92 224 Talc Lubricant 2.8 0.98 56 Sodium Stearyl Fumarate Lubricant 8.0 2.80 160 Core Totals 270.0 94.4 5400 Opadry II *** Coating Aqent 16.0 5.59 320 Purified Water Processing Agent * * * * * * Totals 286.0 100.0 5720 *Amount of hemihydrate, equivalent to 200 mg anhydrous form of drug substance
** Purified water is used during granulation and coating process but removed during the drying process
*** 15 % solid content suspension - Compound (A), D-mannitol and hydroxypropyl cellulose were blended in High Shear Mixer (High Speed Mixer; FS-GS-25J, Fukae Powtex Co., Osaka, Japan) for one minute. The mix was granulated adding purified water. After the completion of adding water, the granulation was continued for two minutes.
- The wet granules were set in fluidized bed drier (Flow Coater; FLO-5M, Freund Co., Tokyo, Japan) and dried. During the drying, the samples of granules were taken from the fluidized bed drier at certain intervals. The moisture level during drying was determined to measure the loss on drying (LOD) of the sample.
- The dried granules were sized with a 22 mesh (710 µm) sieve. The granules of oversized fraction were crushed by using New Speed Mill (ND-10S, Okada Seiko Co. Ltd., Tokyo, Japan) with 2.5 mm and 1.0 mm circular holes screen, followed by passing through a 22 mesh sieve completely.
- Extra-granular Additions (croscarmellose sodium, talc and sodium stearyl fumarate) were premixed with a portion of sized granules in a plastic bag and passed through a 22 mesh (710 µm) sieve respectively. These premixed powders and the residual sized granules were blended for 4 minutes in a V type Blender (SVM-50, Meiwa Kougyo Co., Nagoya, Japan).
- The final blend was compressed into tablets using a rotary press (VIRGO0518SS2AZ, Kikusui Seisakusyo Ltd., Kyoto, Japan) equipped with round biconvex punches of 9 mm in diameter. Tablets were compressed at varying compression forces from 4.2 KN to 6.5 KN. The coefficient of variation in tablet weight was less than 1.0 % and the friability of tablet was less than 0.2 %. Tablet hardness was increased from 67 N to 99 N and the corresponding tablet thickness was decreased from 4.54 mm to 4.35 mm. These results show the good compressibility and compactibility of the final blend. Additionally, In vitro drug release was measured using the Japanese Pharmacopoeia XV(JP XV) apparatus II fitted with paddles rotated at 75 rpm. Dissolution medium was used phosphate buffer pH 6.8 (2nd fluid in JP XV) containing 0.1 % w/w polysorbate 80. A dissolved amount of Compound (A) was between about 90 % and 94 % at 30 minutes. The dissolution rate was not affected by compression force.
- The compressed tablets were coated in aqueous film coating system using Opadry II 15 % solid content suspension based on polyvinyl alcohol. Tablet coating was carried out in a conventional coating pan (Doria coater, DRC-500, Powrex Co., Hyougo, Japan) using spray coating technique and conducted under a generalized manufacturing condition. The tablets were coated without any problem and the prepared tablets were free from defects such as picking and peeling.
- Tablets containing 102 mg of compound (A) hemihydrate (which corresponds to 100 mg of compound (A)) were prepared in accordance with the method described in Example 1. Components and compositions of the tablets are described in Table 2.
Table 2. Composition of Tablet Component mg/tablet Compound (A) 102.0 * D-Mannitol 18.0 Hydroxypropyl Cellulose 4.0 Croscarmellose Sodium 5.6 Talc 1.4 Sodium Stearyl Fumarate 4.0 Opadry II 10.0 * Amount of hemihydrate, equivalent to 100 mg of anhydrous compound (A) - Tablets containing 51 mg of compound (A) hemihydrate were prepared in accordance with the method described in Example 1. Components and compositions of the tablet are described in Table 3.
Table 3. Composition of Tablet Component mg/tablet Compound (A) 51.0 * D-Mannitol 9.0 Hydroxypropyl Cellulose 2.0 Croscarmellose Sodium 2.8 Talc 0.7 Sodium Stearyl Fumarate 2.0 Opadry II 5.5 * Amount of hemihydrate, equivalent to 50 mg of anhydrous compound (A) - Tablets containing 306 mg of compound (A) hemihydrate (which corresponds to 300 mg of compound (A)) were prepared in accordance with the method described below. Components and compositions of the tablets are described in Table 4.
Table 4. Composition of Tablet Component mg/tablet Compound (A) 306.0 * D-Mannitol 54.0 Hydroxypropyl Cellulose 12.0 Croscarmellose Sodium 16.8 Talc 4.2 Sodium Stearyl Fumarate 12.0 * Amount of hemihydrate, equivalent to 300 mg of anhydrous compound (A) - Compound (A), D-mannitol and hydroxypropyl cellulose were blended in High Shear Mixer (Virtical Granulator; VG-100, Powrex Co., Hyogo, Japan) for one minute. The mix was granulated adding purified water. After the completion of adding water, the granulation was continued for two minutes.
- The wet granules were crushed by using New Speed Mill (ND-10S, Okada Seiko Co. Ltd., Tokyo, Japan) with 5.0 mm circular holes screen, and were set in fluidized bed drier (Flow Coater; NFLO-30SJ, Freund Co., Tokyo, Japan) and dried.
- The dried granules were sized with a 22 mesh (710 µm) sieve. The granules of oversized fraction were crushed by using New Speed Mill (ND-10S, Okada Seiko Co. Ltd., Tokyo, Japan) with 5.0 mm, 2.5 mm and 1.0 mm circular holes screen, followed by passing through a 22 mesh sieve completely.
- The sized granules were set in fluidized bed drier (Flow Coater; NFLO-30SJ, Freund Co., Tokyo, Japan) and dried once again.
- During the drying, the samples of granules were taken from the fluidized bed drier at certain intervals. The moisture level during drying was determined to measure the loss on drying (LOD) of the sample.
- Extra-granular additions (croscarmellose sodium, talc and sodium stearyl fumarate) were premixed with a portion of sized granules in a plastic bag and passed through a 22 mesh (710 µm) sieve respectively. These premixed powders and the residual sized granules were blended for 4 minutes in a W type Blender (W-60, Tokujyu Kousakusyo Co., Kanagawa, Japan).
- The final blend was compressed into tablets using a single punch press (Compaction Analyzer, Kikusui Seisakusyo Ltd., Kyoto, Japan) equipped with oval shaped punch (major axis:13.5 mm, minor axis:7.70 mm). Tablets were compressed at varying compression forces from 4.2 KN to 5.4 KN. Tablet hardness was increased from 99 N to 121 N and the corresponding tablet thickness was decreased from 5.12 mm to 5.00 mm. These results show the good compressibility and compactibility of the final blend. Additionally, In vitro drug release was measured using the Japanese Pharmacopoeia XV(JP XV) apparatus II fitted with paddles rotated at 50 rpm. Dissolution medium was used phosphate buffer pH 6.8 (2nd fluid in JP XV) containing 0.1 % w/w polysorbate 80. A dissolved amount of Compound A was between about 77 % and 82 % at 60 minutes. The dissolution rate was not affected by compression force.
- Tablets were prepared in accordance with the method described below, where the components and compositions of the tablets are described in Table 5.
- Compound (A), D-mannitol and hydroxypropyl cellulose were blended in High Shear Mixer (High Speed Mixer; LFS-GS-1, Fukae Powtex Co., Osaka, Japan). The mix was granulated adding purified water. After the completion of adding water, the granulation was continued.
- The wet granules were set in fluidized bed drier (Multiplex; MP-01/03, Powrex Co., Hyougo, Japan) and dried until the product temperature reaches 40 °C.
- The dried granules were sized with a 22 mesh (710 µm) sieve. The granules of oversized fraction were crushed by using Power Mill (P-02S, Dalton Co. Ltd., Tokyo, Japan) with 2 mm herringbone screen and 1.0 mm circular holes screen, followed by passing through a 22 mesh sieve completely.
- Extra-granular additions (croscarmellose sodium, magnesium stearate, talc and sodium stearyl fumarate) were passed through a 42 mesh (355 µm) sieve. These powders and sized granules were put in a plastic bag and mixed 50 times
- Mixed granules were compressed into tablets using a rotary press (Collect 12HUK, Kikusui Seisakusyo Ltd., Kyoto, Japan) equipped with round biconvex punches of 9 mm in diameter. Tablets were compressed at varying compression forces from 0.3 ton to 1.5 ton, and tablet thickness, tablet hardness and ejection force during tableting were measured.
Table 5 Component mg/Tablet Experiment 1 (Ex 1) Experiment 2 (Ex 2) Experiment 3 (Ex 3) Compound (A) 200.0 200.0 200.0 D-mannitol 44.7 44.7 40.0 Hydroxypropyl Methylcellulose 11.4 - - Hydroxypropyl Cellulose - 11.4 8.1 Croscarmellose Sodium 11.2 11.2 11.2 Magnesium Stearate 2.7 - - Sodium Stearyl Fumarate - 2.7 2.7 Talc - - 8.0 Totals 270.0 270.0 270.0 - The results of the ejection force during tableting and the resultant tablet characteristics of thickness and hardness are shown in the following tables.
Ex 1 Compression force (ton) 0.5 0.7 0.9 1.1 thickness (mm) 4.25 4.12 4.09 4.07 hardness (N) 84 109 117 119 Ex 2 Compression force (ton) 0.4 0.8 1.1 1.5 Thickness (mm) 4.37 4.14 4.07 4.00 Hardness (N) 77 137 156 174 Ejection force (kg) 15 20 21 22 Ex 3 Compression force (ton) 0.3 0.5 0.7 0.9 1.1 Thickness (mm) 4.54 4.30 4.15 4.08 4.03 Hardness (N) 51 89 120 141 160 Ejection force (kg) 4 7 10 11 12 -
- 2-(5-Bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene (100 g; see
WO 2005/012326 pamphlet) was dissolved in toluene (300 mL) at room temperature under N2 atmosphere. Sodium iodide (83 g), copper (I) iodide (2.64 g), N,N'-dimethyl ethylenediamine (2.94 mL) and diglyme (50 mL) was added to the mixture at room temperature. The reaction mixture was heated to reflux temperature and stirred for 36 hours. Ethyl acetate (300 mL) was added to the mixture at 40 °C and the mixture was filtered using activated carbon pre-coated filter. The filtrate was washed and then evaporated. The resulting residue was suspended in methanol (426 mL) at reflux temperature for 75 minutes. The resulting slurry was cooled to 25 °C and stirred for 1 hour. The precipitate was filtered and washed with methanol, then dried at 50 °C in vacuo to give 2-(5-iodo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene (94.9 g) as white crystals. m/z (APCI), 409(M++H); mp 109-110 °C. -
- i) i-PrMgCl/LiCl
- ii)
- To a solution of 2-(5-iodo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene (40.0 g) in anhydrous THF (200 mL) was added a solution of i-propyl magnesium chloride / lithium chloride in THF (14.5 wt%, 76.4 g) dropwise under N2 at 0 - 5 °C. The mixture was stirred for 1 hour at the same temperature, and then the mixture was added dropwise to a solution of 2,3,4,6-tetrakis-O-(trimethylsilyl)-D-glucopyrano-1,5-lactone (54.9 g; see
U.S. patent No. 6,515,117 ) in anhydrous THF (80 mL) at 0 - 5 °C. The reaction mixture was stirred for 2 hours and quenched with a solution of methanesulfonic acid (11.3 g) in methanol (400 mL) under cooling. Upon complete addition, the mixture was stirred for 2 hours under cooling , and then was warmed to room temperature and stirred for 4 hours. The mixture was quenched in a solution of NaHCO3 (4.12 g) in H2O (400 mL) under cooling. The mixture was allowed to warm to room temperature, and then n-heptane was added to the mixture. After phase separation, the aqueous phase was extracted with ethyl acetate and toluene. The combined organic layer was washed with 5% aqueous NaHCO3 solution, dried over anhydrous MgSO4, and filtered to afford a solution of methyl 1-C-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucopyranoside in ethyl acetate and toluene. m/z (APCI), 443 (M+-MeOH). -
- To a stirred solution of methyl 1-C-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucopyranoside (net weight 10.54 g) in toluene and ethyl acetate was added N-methylmorpholine (11.9 g) and 4-dimethylaminopyridine (217 mg) at room temperature. The solution was cooled to 0°C and acetic anhydride (52.7 mL) was added dropwise below 15 °C. The reaction mixture was allowed to warm to room temperature and stirred for 15 hours. The mixture was quenched with 28% NH3 aqueous solution (ca. 31.6 mL) while maintaining pH range of 6 to 7. Water was added to the mixture and separated. The organic layer was washed with water and brine, dried over anhydrous MgSO4 and filtered. The filtrate was concentrated in vacuo to give (17.59 g) as yellow oil. m/z (APCI) 660 (M++NH4).
-
- To a stirred solution of the above compound (net weight 14.25 g) in acetonitrile (114 mL) was added triethylsilane (7.74 g) at room temperature. The solution was cooled to 0°C and boron trifluoride etherate (9.45 g) was added dropwise for 10 minutes. The reaction mixture was stirred at 0 °C for 4 hours. The mixture was quenched in a solution of 10% K2CO3 aqueous solution(156.8 mL) under cooling. The mixture was allowed to warm to room temperature and stirred for 15 minutes. After separation, water and ethyl acetate was added to the organic layer. The organic layer was washed with brine, and filtered. The filtrate was concentrated in vacuo. The resulting residue was suspended in ethanol and evaporated (twice). Ethanol was added to the residue and the resulting mixture was stirred for 30 minutes at 50°C, then cooled on an ice-bath. The precipitate was filtered and washed twice with ethanol, then dried to give (1S)-2,3,4,6-tetra-O-acetyl-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol (11.12 g) as white crystals. m/z (APCI) 630 (M++NH4); mp. 160-170 °C.
-
- (1S)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol (5 g) was dissolved in methanol (35 mL) and tetrahydrofuran (25 mL) at room temperature. A solution of LiOH hydrate (192 mg) in water (10 mL) was added dropwise to the mixture for 30 minutes at 20 - 24 °C. After the mixture was stirred for 19 hours at room temperature, the solvent was evaporated in vacuo. The residue was partitioned to ethyl acetate(50 mL) and water (25 mL), stirred for 15 minutes, then the layers were separated. The organic layer was washed with water. The organic layer was dried over Na2SO4, filtered using activated carbon pre-coated filter and evaporated. The resulting residue was dissolved in ethyl acetate (11.1 mL) at 40 °C, water (241 mL) was added to the mixture at the same temperature. n-Heptane (5.6 mL) was added to the mixture at 40 °C, then the mixture was seeded with a slight amount of (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4- methylphenyl)-D-glucitol at same temperature. After stirred for 1 hour at 35°C, n-heptane (2.6 mL) was added slowly to the mixture. The resulting mixture was cooled. The precipitate was filtered and washed with ethyl acetate/n-heptane, then dried to give hemihydrate of (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2- thienyl]methyl}-4-methylphenyl)-D-glucitol (2.93 g) as white crystals. m/z (APCI) 462 (M++NH4); mp. 106-107 °C
Claims (13)
- A tablet comprising a compound of formula (A):
- The tablet according to claim 1, wherein a pharmaceutically acceptable salt of compound (A) is hemihydrate of compound (A).
- The tablet according to claim 1, wherein the pharmaceutically acceptable additives comprise a bulking agent (a filler), a binder, and a disintegrant.
- The tablet of claim 3, wherein a) compound (A) or a pharmaceutically acceptable salt thereof is present in an amount within the range of from 65 to 90 % by weight of tablet; b) the bulking agent (the filler) is present in an amount within the range of from 0 to 70 % by weight of tablet; c) the binder is present in an amount within the range of from 1 to 25 % by weight of tablet; d) the disintegrant is present in an amount within the range of from 1 to 25 % by weight of tablet; and e) the lubricant is present in an amount within the range of from 0.25 to 20 % by weight of tablet.
- The tablet of claim 3, wherein a) compound (A) or a pharmaceutically acceptable salt thereof is present in an amount within the range of from 65 to 90 % by weight of tablet; b) the bulking agent or filler is present in an amount within the range of from 5 to 15 % by weight of tablet; c) the binder is present in an amount within the range of from 1 to 5 % by weight of tablet; d) the disintegrant is present in an amount within the range of from 1 to 5 % by weight of tablet; and e) the lubricant is present in an amount within the range of from 1 to 10 % by weight of tablet.
- The tablet of claim 3, wherein compound (A) or a pharmaceutically acceptable salt thereof is present in an amount of 70 ± 2% by weight of tablet; the bulking agent or filler is present in an amount of 12 ± 2 % by weight of tablet; the binder is present in an amount of 3 ± 1 % by weight of tablet; the disintegrant is present in an amount of 4 ± 1 % by weight of tablet; and the lubricant is present in an amount of 4 ± 2 % by weight of tablet.
- The tablet of claim 6, which further comprises a coating agent in an amount within the range of from 3 to 10 % by weight of tablet.
- The tablet according to claim 1, wherein a) compound (A) hemihydrate is present in an amount of about 204 mg; b) D-mannitol is present in an amount of about 36 mg; c) hydroxypropyl cellulose is present in an amount of about 8 mg; d) croscarmellose sodium is present in an amount of about 11.2 mg; e) talc is present in an amount of about 2.8 mg; and f) sodium stearyl fumarate is present in an amount of about 8 mg.
- The tablet according to claim 1, wherein a) compound (A) hemihydrate is present in an amount of about 102 mg; b) D-mannitol is present in an amount of about 18 mg; c) hydroxypropyl cellulose is present in an amount of about 4 mg; d) croscarmellose sodium is present in an amount of about 5.6 mg; e) talc is present in an amount of about 1.4 mg; and f) sodium stearyl fumarate is present in an amount of about 4 mg.
- The tablet as defined in claim 1 for use in treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis, or hypertension.
- The tablet as defined in claim 1 for use in treating or delaying the progression or onset of type II diabetes or obesity.
- The tablet as defined in claim 1 for use in treating or delaying the progression or onset of diabetes mellitus, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids, elevated blood levels of glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, atherosclerosis, or hypertension, whereby optionally an anti-diabetic agent, an anti-hyperglycemic agent, a hypolipidemic or lipid lowering agent, an anti-obesity agent, an anti-hypertensive agent, or an appetite suppressant is to be administered in combination.
- The tablet as defined in claim 1 alone, or in combination with another antidiabetic agent, an agent for treating diabetic complications, an anti-obesity agent, an anti-hypertensive agent, an anti-platelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent for use in the treatment of type 1 or type 2 diabetes mellitus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33331210P | 2010-05-11 | 2010-05-11 | |
PCT/JP2011/061354 WO2011142478A1 (en) | 2010-05-11 | 2011-05-11 | Canagliflozin containing tablets |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2568971A1 EP2568971A1 (en) | 2013-03-20 |
EP2568971B1 true EP2568971B1 (en) | 2020-10-14 |
Family
ID=44262786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11725825.1A Active EP2568971B1 (en) | 2010-05-11 | 2011-05-11 | Canagliflozin containing tablets |
Country Status (8)
Country | Link |
---|---|
US (2) | US20130052266A1 (en) |
EP (1) | EP2568971B1 (en) |
JP (1) | JP5596799B2 (en) |
KR (1) | KR101869110B1 (en) |
CN (3) | CN105769792A (en) |
ES (1) | ES2836952T3 (en) |
TW (1) | TWI564034B (en) |
WO (1) | WO2011142478A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
JP5900702B2 (en) | 2013-03-29 | 2016-04-06 | アステラス製薬株式会社 | Pharmaceutical composition for oral administration |
US20160083374A1 (en) * | 2013-05-30 | 2016-03-24 | Cadila Healthcare Limited | Amorphous form of canagliflozin and process for preparing thereof |
CN103641822B (en) * | 2013-10-21 | 2016-06-08 | 江苏奥赛康药业股份有限公司 | A kind of Ka Gelie purifies compound and pharmaceutical composition thereof |
US20160280731A1 (en) * | 2013-11-11 | 2016-09-29 | Crystal Pharmatech Co., Ltd | CRYSTALLINE FORMS B, C, and D OF CANAGLIFLOZIN |
CN103655539B (en) * | 2013-12-13 | 2019-09-13 | 重庆医药工业研究院有限责任公司 | A kind of oral solid formulation of canagliflozin and preparation method thereof |
US10174010B2 (en) | 2014-03-19 | 2019-01-08 | Hangzhou Pushai Pharmaceutical Technology Co., Ltd. | Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof |
CN103980262B (en) * | 2014-04-01 | 2016-06-22 | 天津大学 | The B crystal form of canagliflozin and crystallization preparation method thereof |
CN103980261B (en) * | 2014-04-01 | 2016-06-29 | 天津大学 | The A crystal formation of canagliflozin and crystallization preparation method thereof |
EP2947077A1 (en) | 2014-05-19 | 2015-11-25 | LEK Pharmaceuticals d.d. | Stereoselective synthesis of intermediates in the preparation of ß-C-arylglucosides |
TN2016000484A1 (en) * | 2014-05-29 | 2018-04-04 | Novartis Ag | Ceritinib formulation. |
CN105330706B (en) * | 2014-06-05 | 2019-04-16 | 江苏豪森药业集团有限公司 | The preparation method of canagliflozin intermediate |
US20160002275A1 (en) * | 2014-07-03 | 2016-01-07 | Cadila Healthcare Limited | Process for preparation and purification of canagliflozin |
EP2990029A1 (en) | 2014-08-29 | 2016-03-02 | Sandoz Ag | Pharmaceutical compositions comprising Canagliflozin |
CN104402946B (en) * | 2014-11-17 | 2018-01-02 | 连云港恒运药业有限公司 | Canagliflozin intermediate and its unbodied preparation method |
CN105769803A (en) * | 2014-12-16 | 2016-07-20 | 康普药业股份有限公司 | Medicinal composition for treating 2-diabetes mellitus and preparation method of medicinal composition |
JP6027710B1 (en) * | 2014-12-25 | 2016-11-16 | 田辺三菱製薬株式会社 | Solid preparation for diabetes treatment |
CN104523573A (en) * | 2014-12-29 | 2015-04-22 | 成都恒瑞制药有限公司 | Quick-release invokana troche and preparation method thereof |
WO2016142950A1 (en) * | 2015-03-11 | 2016-09-15 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form |
CN106279134A (en) * | 2015-06-23 | 2017-01-04 | 中美华世通生物医药科技(武汉)有限公司 | Canagliflozin monocrystalline and its production and use |
US20170071970A1 (en) * | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
CN106749212A (en) * | 2015-11-24 | 2017-05-31 | 重庆圣华曦药业股份有限公司 | A kind of process for purification of canagliflozin intermediate |
CN105503845A (en) * | 2015-12-01 | 2016-04-20 | 北京普德康利医药科技发展有限公司 | Defluorinated canagliflozin compound, and preparation method and application thereof |
JP2020523408A (en) * | 2017-06-12 | 2020-08-06 | ヤンセン ファーマシューティカ エヌ.ベー. | Method for reducing or preventing cardiovascular events in patients with type 2 diabetes |
CN109553649B (en) * | 2017-09-26 | 2020-12-04 | 北大方正集团有限公司 | Preparation method of canagliflozin intermediate |
CN109553609B (en) * | 2017-09-26 | 2020-09-04 | 北大方正集团有限公司 | Preparation method of canagliflozin |
US11857559B2 (en) | 2018-09-10 | 2024-01-02 | Aurobindo Pharma Ltd. | Pharmaceutical composition comprising Canagliflozin, process of preparation and use thereof |
CN110946840B (en) * | 2019-12-31 | 2021-11-26 | 常州恒邦药业有限公司 | Canagliflozin pharmaceutical composition and preparation method thereof |
WO2024053680A1 (en) * | 2022-09-07 | 2024-03-14 | 田辺三菱製薬株式会社 | Orally disintegrating tablet |
CN115531376A (en) * | 2022-10-26 | 2022-12-30 | 河南省人民医院 | Novel application of canagliflozin in flora regulation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6635278B1 (en) * | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
AU2001294192A1 (en) * | 2000-10-06 | 2002-04-22 | Takeda Chemical Industries Ltd. | Solid preparations |
PT2896397T (en) | 2003-08-01 | 2017-11-23 | Mitsubishi Tanabe Pharma Corp | Novel compounds having inhibitory activity against sodium-dependant glucose transporter |
UY30730A1 (en) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE |
TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
CL2008002425A1 (en) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Pharmaceutical composition comprising an inhibitor of sglt2 and 1- (4-methyl-quinazolin-2-yl) methyl-3-methyl-7 - (- 2-butin-1-yl) -8- (3- (r) -amino- Piperidin-1yl) -xanthine, an iv dpp inhibitor and its use for the treatment of obesity and type 1 and 2 diabetes and complications thereof. |
NZ594487A (en) * | 2009-02-13 | 2013-11-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
-
2011
- 2011-05-11 TW TW100116437A patent/TWI564034B/en active
- 2011-05-11 ES ES11725825T patent/ES2836952T3/en active Active
- 2011-05-11 WO PCT/JP2011/061354 patent/WO2011142478A1/en active Application Filing
- 2011-05-11 CN CN201610158907.XA patent/CN105769792A/en active Pending
- 2011-05-11 CN CN2011800233805A patent/CN102985075A/en active Pending
- 2011-05-11 KR KR1020127032207A patent/KR101869110B1/en active IP Right Grant
- 2011-05-11 US US13/697,225 patent/US20130052266A1/en not_active Abandoned
- 2011-05-11 JP JP2012551398A patent/JP5596799B2/en active Active
- 2011-05-11 EP EP11725825.1A patent/EP2568971B1/en active Active
- 2011-05-11 CN CN201610946887.2A patent/CN106890147A/en active Pending
-
2016
- 2016-04-20 US US15/133,889 patent/US9655852B2/en active Active
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
JP2013526482A (en) | 2013-06-24 |
CN102985075A (en) | 2013-03-20 |
US20130052266A1 (en) | 2013-02-28 |
KR20130106279A (en) | 2013-09-27 |
ES2836952T3 (en) | 2021-06-28 |
CN106890147A (en) | 2017-06-27 |
CN105769792A (en) | 2016-07-20 |
KR101869110B1 (en) | 2018-06-19 |
WO2011142478A1 (en) | 2011-11-17 |
US20160228375A1 (en) | 2016-08-11 |
TWI564034B (en) | 2017-01-01 |
US9655852B2 (en) | 2017-05-23 |
TW201200164A (en) | 2012-01-01 |
JP5596799B2 (en) | 2014-09-24 |
EP2568971A1 (en) | 2013-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9655852B2 (en) | Tablets containing a 1-(β-D-glucopyranosyl)-3-(phenylthienylmethyl)benzene compound | |
AU2017210661B2 (en) | Pharmaceutical formulations comprising 1-(beta-D-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of SGLT | |
KR20180079176A (en) | Pharmaceutical combination comprising DAPAGLIFLOZIN L-PROLINE and antidiabetic drugs | |
WO2003082262A2 (en) | Compositions of venlafaxine base | |
CN113045525B (en) | Preparation method of C-glucoside derivative and preparation thereof | |
CN106955273B (en) | Pharmaceutical composition containing sodium-glucose cotransporter 2 inhibitor | |
CN101684103B (en) | Compound with 1,2,4-triazole structure and preparation method and application thereof | |
US20230346817A1 (en) | Composition and use of sglt-2 inhibitor and angiotensin receptor blockers | |
CN117677378A (en) | Oral composite tablet comprising sitagliptin, dapagliflozin and metformin | |
EP4008315A1 (en) | A process for formulations of dapagliflozin and metformin hydrochloride | |
WO2017153939A1 (en) | Pharmaceutical composition comprising canagliflozin, process of preparation and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20121206 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MITSUBISHI TANABE PHARMA CORPORATION |
|
17Q | First examination report despatched |
Effective date: 20151120 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/7042 20060101ALI20200416BHEP Ipc: A61P 3/08 20060101ALI20200416BHEP Ipc: A61P 13/12 20060101ALI20200416BHEP Ipc: A61K 9/28 20060101ALI20200416BHEP Ipc: A61K 31/7034 20060101ALI20200416BHEP Ipc: A61P 3/10 20060101ALI20200416BHEP Ipc: A61P 27/02 20060101ALI20200416BHEP Ipc: A61K 31/381 20060101ALI20200416BHEP Ipc: A61P 25/00 20060101ALI20200416BHEP Ipc: A61P 3/04 20060101ALI20200416BHEP Ipc: A61P 9/10 20060101ALI20200416BHEP Ipc: A61K 9/20 20060101AFI20200416BHEP Ipc: A61P 9/12 20060101ALI20200416BHEP Ipc: A61P 17/02 20060101ALI20200416BHEP Ipc: A61P 3/06 20060101ALI20200416BHEP |
|
INTG | Intention to grant announced |
Effective date: 20200504 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TOKUDA TAKAYUKI Inventor name: SUGIMOTO MASAAKI Inventor name: KINOSHITA HAJIME |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: TOKUDA TAKAYUKI Inventor name: KINOSHITA HAJIME Inventor name: SUGIMOTO MASAAKI |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1322893 Country of ref document: AT Kind code of ref document: T Effective date: 20201015 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011068922 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1322893 Country of ref document: AT Kind code of ref document: T Effective date: 20201014 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20201014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210114 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210215 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210115 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210214 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210114 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2836952 Country of ref document: ES Kind code of ref document: T3 Effective date: 20210628 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011068922 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 |
|
26N | No opposition filed |
Effective date: 20210715 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210511 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20210531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210511 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210214 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20210531 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110511 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20201014 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20230330 Year of fee payment: 13 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230426 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20230412 Year of fee payment: 13 Ref country code: FR Payment date: 20230411 Year of fee payment: 13 Ref country code: ES Payment date: 20230601 Year of fee payment: 13 Ref country code: DE Payment date: 20230331 Year of fee payment: 13 |